WELTRUZA™ (olanzapine) Approval – Conference Call - TEVA PHARMACEUTICAL INDUSTRIES LTD

Financial Performance:

• Teva has not disclosed specific quarterly revenue or profit margin impacts from Welltrusa for the current reporting period, as the product is in the pre-launch phase.
• Wholesale Acquisition Cost (WAC) is set at $3,950, representing a flat pricing strategy across all doses (contrasting with the tiered pricing of previous launches like Uzedy).
• Revenue realization is expected to be minimal in H1 of the following year, with meaningful contribution anticipated to begin in the second half of the next year.
• The company projects a combined peak annual run-rate revenue potential of $1.5 billion to $2.0 billion for the Uzedy and Welltrusa franchise once mature.
• The launch trajectory relies heavily on the speed of Medicaid state-by-state formulary approvals and hospital formulary placements as primary gating factors for revenue ramp.

Guidance and Future Outlook:

• The company reaffirms its "Pivot to Growth" strategy, transitioning from a defense-focused entity to a world-class biopharmaceutical company.
• Management targets a 13% to 14% Long-Acting Injectable (LAI) penetration rate for schizophrenia patients, drawing analogies from current market data where approximately 13-14% of the total LAI market exists.
• Long-term goals include exploring life-cycle management opportunities, specifically investigating the bipolar mania indication for the olanzapine LAI molecule.
• Future growth is driven by the commercial synergy between the new Welltrusa launch and the established Uzedy franchise, aiming to cover approximately 80% of the schizophrenia patient population on LAIs.

Business Segments and Product Lines:

• Welltrusa (Lanzapine LAI): FDA-approved once-monthly subcutaneous injection for schizophrenia; key differentiators include no loading dose, no oral supplementation, no post-injection monitoring, and immediate therapeutic levels.
• Uzedy: Existing LAI franchise (paliperidone palmitate) used as a strategic co-launch partner to provide a comprehensive coverage of the schizophrenia market.
• Launch Strategy: Direct-to-consumer (DTC) campaign targeting patients, families, and physicians to drive awareness; sales force of over 1,000 reps is trained to cover 80% of the target physician universe.
• Distribution: Utilizing specialty pharmacy and direct hospital kits; no reliance on waiting for a permanent J-code to initiate commercial activity.
• Pipeline: Recent milestones include ECOPIPE accepted for priority review, NCR15 data in vitiligo, and data in celiac disease, alongside the successful Welltrusa approval.

Market and Competitive Landscape:

• The total addressable market includes 2.2 million U.S. patients with schizophrenia, 1.5 million of whom are treated, with oral olanzapine representing approximately 20% of the oral antipsychotic market.
• Welltrusa addresses a significant unmet need as the first viable long-acting injectable for olanzapine, a molecule with a 20% oral market share but no prior LAI option.
• Competitors include intramuscular LAIs requiring monitoring and loading doses; Welltrusa differentiates via subcutaneous administration and streamlined administration protocols.
• Market trends indicate a strong physician demand for LAIs to prevent relapse, though historical LAI penetration remains low due to logistical hurdles.

Risks and Challenges:

• Payer Access: Medicaid reimbursement varies significantly by state, with some states taking up to 12 months to approve, potentially delaying revenue ramp.
• Metabolic Risks: Olanzapine carries inherent metabolic risks (weight gain); while the safety profile mirrors the oral version, discontinuation rates due to side effects remain a monitoring parameter.
• Patient Adherence: Despite the LAI format, patient drop-off and adherence to long-term therapy remain critical challenges in the schizophrenia market.
• Competitive Substitution: Potential competition from newer LAIs or off-label usage of other agents may impact market share capture.

Management Commentary and Tone:

• Management tone is highly optimistic and confident, characterizing the Welltrusa approval as a "special day" and a "winning paradigm" for the company's R&D strategy.
• Richard Francis (SVP IR) and Eric Hughes (CMO) emphasize the patient-centric nature of the approval and the strategic execution of the pivot to growth.
• The company expresses pride in the "innovation by design" approach that accelerated development by 6-9 months and secured "right-first-time" approval.
• Leadership highlights the synergy between commercial and R&D teams, noting extensive preparation and a "shiny toy" product that complements the existing Uzedy portfolio.

Analyst Questions and Answers:

• Target Patient Profile: Analysts asked about patient targeting; management clarified that the primary target is patients currently on oral olanzapine, with potential for switches from other LAIs.
• Pricing Strategy: Clarification was provided on the flat pricing model ($3,950) designed to maximize broad access without disincentivizing specific doses, contrasting with previous tiered pricing.
• Launch Trajectory: Q&A confirmed that meaningful revenue is delayed until H2 of next year due to the Medicaid formulary ramp-up process, though leading indicators (samples, scripts) will appear earlier.
• Differentiation vs. Uzedy: Management affirmed that both products will be prioritized, covering 80% of the schizophrenia market, with distinct value propositions for different patient segments.
• Technology & Label: Discussion highlighted the unique MedinCell platform, with label data explicitly noting the rapid dissolution rate (91% vs. 7% for comparators) and the absence of significant post-marketing requirements other than pharmacovigilance.
• Future Indications: Management acknowledged ongoing discussions regarding the bipolar mania indication as a potential future expansion.

Other Key Points:

• Relapse Data: Post-injection follow-up data (SOLARIS study) showed a 4% relapse rate (96% stability), underscoring the efficacy of the LAI in preventing breakthrough symptoms.
• Logistical Ease: The product eliminates post-injection monitoring and loading doses, removing common barriers to LAI adoption for physicians.
• Patient Hub: A dedicated, bespoke patient support hub is being deployed to optimize access and manage out-of-pocket costs, mirroring the strategy used for Uzedy.
• Global Context: Market research indicates higher LAI penetration in Europe (slightly above 14%), suggesting potential for similar growth dynamics in the U.S. with the right product.